Boston Scientific Corporation

Boston Scientific develops, manufactures and sells medical devices across cardiovascular, endoscopy, urology and neuromodulation specialties. Hospitals, clinics and other providers buy the products, often using third-party reimbursement to pay for procedures; many devices are single-use, while implanted products can also support follow-on services such as remote monitoring. The economics are understandable: device sales and procedure volumes generate revenue, while the company funds a large sales organization, research and development, regulatory work and manufacturing. It wins with differentiated clinical products, physician familiarity and a broad specialist commercial network, rather than with a single protected patent or an unchallenged franchise. Proven devices and established physician workflows should remain valuable as long as less-invasive procedures and reliable clinical outcomes matter, though individual products can be displaced. Revenue reached $20.1 billion in 2025, and operating cash flow less capital spending was $3.66 billion; first-half 2026 organic sales growth was 8.1%, with competition and slower growth in some franchises also evident. I estimate normalized owner earnings at $3.2–4.0 billion annually, treating stock compensation as a cost and not relying on acquisition-adjusted earnings as if amortization and deal activity were irrelevant. The business appears to be a slow compounder: internal innovation and product launches support growth, but acquisitions are frequent and have sometimes led to impairments or discontinued programs. The pending Penumbra acquisition, expected to require substantial new debt, and the $1.6 billion MiRus investment with further milestone-dependent commitments make capital allocation and returns on new investments important to watch. Management's performance-linked pay and the absence of buybacks in 2024 and 2025 are positives, but the large 2026 repurchase alongside substantial investment and acquisition commitments leaves capital discipline mixed. A conservative equity value range is $70–110 billion, based on that earning-power range, modest growth supported by reinvestment, a demanding owner hurdle and allowance for debt and deal risk; product failures, regulatory or quality problems, reimbursement pressure, or acquisitions that do not earn their cost could materially impair the case.